BJMO - volume 19, issue 4, june 2025
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, J. Ibrahim PhD, O. Islam MD, S. Chhajlani MD, A. Florez Romero MD, C. De Weerdt MSc, K. Blockhuys MSc, L. Verbruggen PhD, S. Raats MSc, D. Van Genechten , H. Leupe MD, I. Borbath MD, PhD, C. Deroose MD, PhD
During the ENETS Conference, the long-awaited results of the phase 3 COMPETE trial were presented, with the comparison of [177Lu]Lu-edotreotide (Peptide Receptor Radionuclide Therapy = PRRT) vs. everolimus in patients with grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP NET): PRRT outperformed everolimus in terms of objective response rate and also progression-free survival. Also, an update of the phase 2 OCCLURANDOM trial showed the superiority of PRRT vs. sunitinib in a direct comparison between these two treatment modalities. Alpha-PRRT is advancing in the field of NET as a promising treatment option, with the ACTION-1 trial actively recruiting now in Belgium. NET-IMPRESS, a novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies, was rewarded as the most promising basic research project during the conference and will be tested in broader patient populations. Also, the prominent presence of the patient organisations INCA/VZW NET & MEN at ENETS coincides with the rapidly growing field of treatment options in recent years for our patients with NET.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2025;19(4):166–184)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
